Your browser is no longer supported. Please, upgrade your browser.
Settings
AKBA Akebia Therapeutics, Inc. daily Stock Chart
AKBA [NASD]
Akebia Therapeutics, Inc.
Index- P/E- EPS (ttm)-2.54 Insider Own1.20% Shs Outstand123.05M Perf Week-4.87%
Market Cap504.50M Forward P/E- EPS next Y-0.65 Insider Trans0.00% Shs Float108.00M Perf Month-29.19%
Income-192.60M PEG- EPS next Q-0.32 Inst Own72.20% Short Float7.25% Perf Quarter-49.82%
Sales234.50M P/S2.15 EPS this Y-46.10% Inst Trans3.82% Short Ratio6.59 Perf Half Y-54.14%
Book/sh4.84 P/B0.85 EPS next Y56.40% ROA-28.50% Target Price17.33 Perf Year-61.14%
Cash/sh1.37 P/C3.00 EPS next 5Y- ROE-51.00% 52W Range4.10 - 11.60 Perf YTD-25.86%
Dividend- P/FCF- EPS past 5Y8.10% ROI-23.00% 52W High-64.66% Beta1.42
Dividend %- Quick Ratio1.10 Sales past 5Y- Gross Margin87.50% 52W Low0.00% ATR0.26
Employees325 Current Ratio1.70 Sales Q/Q58.40% Oper. Margin-97.90% RSI (14)24.07 Volatility4.56% 5.38%
OptionableYes Debt/Eq0.00 EPS Q/Q-28.40% Profit Margin-82.10% Rel Volume0.62 Prev Close4.28
ShortableYes LT Debt/Eq0.00 EarningsMay 09 BMO Payout- Avg Volume1.19M Price4.10
Recom2.10 SMA20-15.08% SMA50-30.35% SMA200-42.05% Volume732,266 Change-4.21%
May-02-19Initiated JP Morgan Overweight $12
Mar-20-19Initiated Citigroup Neutral $9
Sep-07-18Resumed Morgan Stanley Equal-Weight
Aug-10-18Reiterated Needham Buy $20 → $18
Jun-06-18Reiterated H.C. Wainwright Buy $24 → $22
Dec-19-17Initiated Piper Jaffray Overweight $26
Dec-07-17Initiated BTIG Research Buy $30
Sep-15-17Initiated RBC Capital Mkts Sector Perform $17
Jul-10-17Reiterated H.C. Wainwright Buy $25 → $24
Apr-27-17Reiterated Needham Buy $14 → $18
Apr-27-17Reiterated H.C. Wainwright Buy $18 → $21
Dec-27-16Reiterated H.C. Wainwright Buy $17 → $18
Dec-20-16Reiterated JMP Securities Mkt Outperform $16 → $19
Nov-15-16Initiated Aegis Capital Buy
Sep-29-16Initiated Brean Capital Buy
Mar-16-16Reiterated Needham Buy $18 → $14
Jan-21-16Initiated Credit Suisse Neutral
Dec-15-15Reiterated Needham Buy $14 → $18
Dec-15-15Reiterated H.C. Wainwright Buy $24 → $25
Dec-07-15Initiated H.C. Wainwright Buy $24
Jun-11-19 07:30AM  Akebia Therapeutics Launches AkebiaCares, an Enhanced Patient Access Program for People with Chronic Kidney Disease Business Wire
Jun-04-19 04:05PM  Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
May-29-19 08:00AM  Akebia Therapeutics to Participate in Upcoming Investor Conferences Business Wire
May-22-19 02:56AM  Edited Transcript of AKBA earnings conference call or presentation 9-May-19 1:00pm GMT Thomson Reuters StreetEvents
May-09-19 02:44PM  Akebia Therapeutics, Inc. (AKBA) Q1 2019 Earnings Call Transcript Motley Fool
01:16PM  Heres What Hedge Funds Think About Akebia Therapeutics Inc (AKBA) Insider Monkey
08:10AM  Akebia Therapeutics: 1Q Earnings Snapshot Associated Press
08:00AM  Akebia Therapeutics Reports First Quarter 2019 Financial Results; Announces Full Enrollment of Phase 3 INNO2VATE Studies and Announces Key Executive Appointments Business Wire
May-08-19 11:45AM  Seth Klarman Keeps Buying This Biotech Stock GuruFocus.com
May-02-19 04:05PM  Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
10:32AM  Will Akebia Therapeutics (AKBA) Report Negative Earnings Next Week? What You Should Know Zacks
08:00AM  Akebia and Otsuka Pharmaceutical Development & Commercialization Inc (OPDC) Announce Presentation of Four Posters at the NKF 2019 Spring Clinical Meetings Business Wire
Apr-30-19 08:00AM  Akebia Therapeutics to Report First Quarter 2019 Financial Results Business Wire
Apr-10-19 10:30AM  Akebia Expands Vadadustat Licensing Deal With Vifor Pharma Zacks
Apr-09-19 01:00AM  Vifor Pharma and Akebia Therapeutics Announce Expansion of License Agreement Business Wire
01:00AM  Vifor Pharma and Akebia Therapeutics Announce Expansion of Licence Agreement Business Wire
Apr-05-19 04:19PM  Akebia Therapeutics to Present at the 18th Annual Needham Healthcare Conference Business Wire
Apr-02-19 04:05PM  Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire -13.04%
Apr-01-19 08:00AM  Medison to Nominate Six Highly Qualified Directors for Knight Therapeutics' Board to Strengthen Oversight and Drive Value Creation for All Shareholders CNW Group
Mar-27-19 07:20AM  Consolidated Research: 2019 Summary Expectations for ADT, HudBay Minerals, Whirlpool, Akebia Therapeutics, Nevro, and MicroStrategy Fundamental Analysis, Key Performance Indications GlobeNewswire
Mar-26-19 05:48PM  Akebia Therapeutics Inc (AKBA) Files 10-K for the Fiscal Year Ended on December 31, 2018 GuruFocus.com
Mar-21-19 02:52AM  Edited Transcript of AKBA earnings conference call or presentation 18-Mar-19 8:30pm GMT Thomson Reuters StreetEvents
Mar-19-19 01:11AM  Akebia Therapeutics (AKBA) Q4 2018 Earnings Conference Call Transcript Motley Fool
Mar-18-19 04:05PM  Akebia Therapeutics Announces Preliminary Full-Year 2018 Financial Results and Business Highlights Business Wire
Mar-12-19 04:35PM  Why Akebia Therapeutics, Momo, and Switch Jumped Today Motley Fool +10.35%
11:55AM  Why Akebia Therapeutics Is Soaring Today Motley Fool
07:47AM  The Daily Biotech Pulse: Zafgen Won't File IND For Metabolic Disorder Drug, Positive Results For Akebia's Anemia Drug Benzinga
04:00AM  Akebia Therapeutics Announces Positive Top-Line Results from Two Pivotal Phase 3 Studies of Vadadustat in Japanese Patients with Anemia Due to Chronic Kidney Disease Business Wire
Mar-11-19 10:30AM  Analysts Estimate Akebia Therapeutics (AKBA) to Report a Decline in Earnings: What to Look Out for Zacks
Mar-06-19 07:00AM  Akebia Therapeutics to Host Fourth Quarter and Full-Year 2018 Investor Update Call and Webcast Business Wire
Mar-04-19 04:05PM  Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Feb-19-19 07:18AM  Akebia Therapeutics, Inc. (NASDAQ:AKBA) Is Trading At A 29.34% Discount Simply Wall St.
Feb-14-19 05:09PM  Seth Klarman Disculoses 4th-Quarter Stock Purchases GuruFocus.com
Feb-04-19 04:05PM  Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire +7.21%
07:50AM  Report: Developing Opportunities within T-Mobile US, Noble, Akebia Therapeutics, Vornado Realty Trust, Bio-Rad Laboratories, and Standex International Future Expectations, Projections Moving into 2019 GlobeNewswire
Jan-30-19 09:18AM  Akebia Therapeutics (AKBA) Upgraded to Buy: Here's What You Should Know Zacks +5.15%
Jan-18-19 09:17AM  What Did Akebia Therapeutics, Inc.s (NASDAQ:AKBA) CEO Take Home Last Year? Simply Wall St.
Jan-02-19 04:05PM  Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
07:00AM  Akebia Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference Business Wire
Dec-16-18 11:36PM  Hedge Funds Are Crazy About Akebia Therapeutics Inc (AKBA) Insider Monkey
Dec-14-18 05:10PM  Seth Klarman Gains Stake in Akebia Therapeutics GuruFocus.com -12.20%
11:27AM  Abrams Capital Managements Return, AUM and Holdings Insider Monkey
Dec-13-18 04:30PM  Akebia Poised To Become 'Renal Powerhouse' With Keryx Merger, Raymond James Says Benzinga
10:55AM  Why Akebia Therapeutics Is Soaring Today Motley Fool
07:00AM  Akebia Therapeutics and Keryx Biopharmaceuticals Complete Merger, Creating Fully Integrated Renal Company Business Wire
Dec-11-18 12:00PM  Akebia Therapeutics Shareholders Approve Merger with Keryx Business Wire
Dec-03-18 04:05PM  Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Nov-30-18 08:55AM  Leading Independent Proxy Advisory Firm Glass Lewis Joins ISS in Recommending Akebia Shareholders Vote FOR Proposed Merger with Keryx Business Wire
08:55AM  Glass Lewis Recommends that Keryx Biopharmaceuticals Stockholders Vote FOR the Proposed Merger with Akebia Therapeutics GlobeNewswire
Nov-29-18 08:35AM  Report: Developing Opportunities within Teleflex, Anthem, Crown Castle International, MSCI, GCI Liberty, and Akebia Therapeutics Future Expectations, Projections Moving into 2018 GlobeNewswire
07:00AM  Leading Independent Proxy Advisory Firm ISS Recommends Akebia Shareholders Vote FOR Proposed Merger with Keryx Business Wire
07:00AM  ISS Recommends that Keryx Biopharmaceuticals Stockholders Vote FOR the Proposed Merger with Akebia Therapeutics GlobeNewswire
Nov-21-18 01:41PM  What Kind Of Shareholders Own Akebia Therapeutics Inc (NASDAQ:AKBA)? Simply Wall St.
Nov-20-18 04:05PM  Akebia Therapeutics to Participate in Upcoming Investor Conferences Business Wire
Nov-16-18 08:08AM  The Daily Biotech Pulse: Mallinckrodt FDA Verdict, European Cheer For Bristol-Myers Squibb, Morphosys Clinches Licensing Deal Benzinga
Nov-15-18 05:15PM  Akebia Therapeutics and Keryx Biopharmaceuticals Announce Chairperson for Combined Company Business Wire +5.74%
Nov-14-18 12:11PM  David Abrams Buys 3 Stocks in 3rd Quarter GuruFocus.com
Nov-13-18 04:05PM  Akebia Therapeutics Sends Letter to Shareholders Business Wire
Nov-08-18 05:40PM  Akebia Therapeutics (AKBA) Reports Q3 Loss, Tops Revenue Estimates Zacks
04:36PM  Akebia Therapeutics: 3Q Earnings Snapshot Associated Press
04:30PM  Akebia Therapeutics Announces Third Quarter 2018 Financial Results Business Wire
Nov-07-18 10:30AM  Analysts Estimate Akebia Therapeutics (AKBA) to Report a Decline in Earnings: What to Look Out for Zacks +8.41%
Nov-02-18 04:05PM  Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Oct-30-18 05:35PM  Akebia Therapeutics Files Definitive Proxy Statement in Connection with Proposed Merger with Keryx Biopharmaceuticals Business Wire
05:31PM  Keryx Biopharmaceuticals Announces Filing of Definitive Joint Proxy Statement in Connection with Pending Merger with Akebia Therapeutics GlobeNewswire
Oct-19-18 09:25AM  Report: Developing Opportunities within VICI Properties, Transocean, Akebia Therapeutics, Welltower, Golden Star Resources, and Casa Future Expectations, Projections Moving into 2018 GlobeNewswire
Oct-09-18 04:05PM  Akebia Therapeutics Announces Presentations at the American Society of Nephrology Kidney Week 2018 Annual Meeting Business Wire
Oct-02-18 04:05PM  Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Oct-01-18 11:38AM  Endo Recalls 2 Lots of Robaxin Tablets Due to Labeling Error Zacks
Sep-25-18 04:05PM  Akebia Therapeutics to Participate in Upcoming Investor Conferences Business Wire
Sep-14-18 11:19AM  What Investors Should Know About Akebia Therapeutics Incs (NASDAQ:AKBA) Financial Strength Simply Wall St.
Sep-04-18 04:05PM  Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Aug-30-18 04:05PM  Akebia Therapeutics to Participate in Upcoming Investor Conferences Business Wire
Aug-29-18 11:52AM  5 Healthcare Stocks That Are Down, But Not Out! InvestorPlace
Aug-28-18 04:05PM  Akebia Therapeutics Appoints Cynthia Smith to Its Board of Directors Business Wire
Aug-21-18 08:30AM  Report: Exploring Fundamental Drivers Behind Oaktree Specialty Lending, uniQure N.V, Mercury, Akebia Therapeutics, Mitel Networks, and Greenlight Capital Re New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Aug-19-18 09:45PM  Edited Transcript of AKBA earnings conference call or presentation 8-Aug-18 8:30pm GMT Thomson Reuters StreetEvents
Aug-09-18 11:57AM  Keryx's (KERX) Loss Wider Than Expected in Q2, Sales Lag Zacks -15.43%
08:39AM  The Daily Biotech Pulse: Ampio Slides On Offering, Sangamo's Positive Trial Results, Insys Earnings Benzinga
Aug-08-18 07:25PM  Akebia Therapeutics (AKBA) Reports Q2 Loss, Tops Revenue Estimates Zacks
06:19PM  Akebia Therapeutics: 2Q Earnings Snapshot Associated Press
04:05PM  Akebia Therapeutics Announces Second Quarter 2018 Financial Results Business Wire
02:30PM  Akebia Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Aug-02-18 04:05PM  Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Aug-01-18 04:05PM  Akebia Therapeutics to Host Second Quarter 2018 Investor Update Call and Webcast Business Wire
Jul-30-18 02:00PM  7 Health Care Stocks to Buy for Robust Returns Kiplinger
Jul-06-18 03:07PM  INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Regarding Whether the Sale of Keryx Biopharmaceuticals, Inc. to Akebia Therapeutics, Inc. is Fair to Shareholders GlobeNewswire
Jul-05-18 06:17PM  Biotech Stock Roundup: GILD's Positive CHMP Nod, Regulatory Updates & More Zacks
Jul-02-18 04:05PM  Akebia Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Business Wire
Jun-29-18 07:12PM  WeissLaw LLP Investigates Keryx Biopharmaceuticals Inc. PR Newswire +6.62%
09:08AM  Keryx (KERX) Inks Merger Deal With Akebia, Shares Fall Zacks
Jun-28-18 11:21AM  Here's Why Keryx Biopharmaceuticals and Akebia Therapeutics Are Plunging Today Motley Fool -9.83%
07:00AM  Akebia Therapeutics and Keryx Biopharmaceuticals to Merge, Creating a Fully Integrated Company Focused on the Development and Commercialization of Therapeutics for Patients with Kidney Disease Business Wire
Jun-26-18 07:51PM  Ex-Akebia employee jailed for night as insider trading trial starts Reuters
04:02PM  Ex-Akebia employee jailed for night as insider trading trial starts Reuters
Jun-11-18 07:40AM  Todays Free Research Reports Coverage on Agenus and Three More Biotech Stocks ACCESSWIRE
Jun-06-18 08:10AM  Investor Expectations to Drive Momentum within Core-Mark Holding, SSR Mining, iRhythm Technologies, Magic Software Enterprises, Jounce Therapeutics, and Akebia Therapeutics Discovering Underlying Factors of Influence GlobeNewswire +5.09%
Jun-04-18 04:05PM  Akebia Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Business Wire
May-15-18 04:05PM  Akebia Therapeutics to Present at Upcoming Investor Conference Business Wire
May-09-18 05:16PM  Akebia Therapeutics: 1Q Earnings Snapshot Associated Press
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its lead product candidate includes Auryxia, a ferric citrate to control the serum phosphorus levels in adult patients with chronic kidney disease (CKD), on dialysis (DD)-CKD, or the hyperphosphatemia indication (HIF); and vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to CKD in DD and non-dialysis patients. It has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat in the United States, European Union, Russia, China, Australia, Canada, the Middle East, and other countries; and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of HIF-prolyl hydroxylases-targeted compounds worldwide. The company was founded in 2007 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Butler John P.CEO and PresidentJun 03Option Exercise0.47287,000134,890836,232Jun 05 04:05 PM
Butler John P.CEO and PresidentJul 11Option Exercise0.47100,00047,000510,314Jul 12 04:59 PM